BioMarin CEO, waiting on FDA on Duchenne drug, eyes Europe

SAN FRANCISCO (Reuters) - BioMarin Pharmaceutical is expecting U.S. regulators to take action this month on its drug to treat a fatal muscle-wasting disease but is also eyeing the European market, its chief executive officer said in an interview.

http://ift.tt/1Zmo5Cc

from Reuters: Health News
via animenewspro